查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1806547

按产品类型、测试类型、样本类型、技术、便携性、购买模式、应用、最终用户和分销管道就地检验市场 - 全球预测 2025-2030

Point of Care Testing Market by Product, Test Type, Sample Type, Technology, Portability, Mode of Purchase, Application, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计就地检验到 2024 年将达到 328.7 亿美元，到 2025 年将达到 371.3 亿美元，到 2030 年将达到 691.7 亿美元，复合年增长率为 13.19%。

主要市场统计数据
基准年2024年 328.7亿美元
预计2025年 371.3亿美元
预测年份 2030 691.7亿美元
复合年增长率（%） 13.19%

清晰的行业介绍，重点介绍分散诊断、先进检测和数位融合如何重新定义临床决策路径

即时检测 (POC) 持续重塑诊断技术，使及时的临床决策更贴近患者。本介绍概述了即时检测生态系统的现代轮廓，重点介绍了分散式诊断、数位连接和治疗决策支援的融合。随着医疗保健系统优先考虑快速分流、基于价值的护理和门诊病人管理，POC 模式因其缩短临床等待时间和改善患者体验的能力而日益受到重视。

多重检测、连结性和护理服务模式的进步如何推动分散诊断实践的系统变革

在技​​术、医疗服务模式和患者期望的推动下，就地检验领域正在经历一场变革。首先，技术发展轨迹正从单一分析物快速检测转向多路復用平台和整合分子工作流程，从而能够在需要时进行更广泛的诊断。同时，感测器微型化和微流体整合正在减少样本量和周转时间，使家庭和门诊检测更加可行。

评估 2025 年美国关税对 POC 检测相关人员的多方面业务和供应链影响

2025年美国实施的关税和贸易措施将对即时检测 (POC) 领域的製造商、供应商和最终用户产生复杂影响。对零件、耗材和成品设备征收的关税将增加依赖全球供应链的产品到岸成本，并可能影响筹资策略和重新订购时机。由于许多仪器和试剂包含来自多个地区的电子元件、塑胶零件和精密加工零件，因此关税导致的成本增加可能会因特定子零件的产地而异。

综合細項分析，整合产品、技术、测试类型、可移植性、购买模式、应用、最终用户、样本类型和分销渠道动态，为您的战略提供信息

细分洞察揭示了产品类型、检测类型、样本基质、技术、便携性选项、采购模式、应用、最终用户和分销管道如何影响需求模式和开发优先顺序。在产品细分中，耗材、服务和软体、仪器和分析仪以及试剂和检测方法各自具有不同的意义。耗材、配件、服务维护和校准以及软体和连接性支援持续的收益流和业务连续性；桌上型分析仪、分子平台、可携式分析仪、读取器和扫描仪决定了部署场景和临床工作流程；血糖试纸、血液学试剂、免疫检测测定试剂、横向流动化验试剂和分子检测试剂套件推动特定检测的供应链纸和品质保证。

美洲、中东和非洲以及亚太地区的地理差异将如何影响 POC 的采购、监管和部署

区域差异显着影响着即时检验 (POC) 检测的设计、部署和报销方式，美洲、欧洲、中东和非洲以及亚太地区各自呈现出不同的市场驱动力和营运考量。在美洲，医疗保健系统优先考虑门诊病人护理优化和慢性病管理，这催生了对支持远端监控以及在诊所和家庭环境中进行快速心血管和代谢检测的设备和检测法的需求。该地区的分销网络优先考虑整合供应链和本地化服务支持，青睐那些能够提供强大售后服务并与主流电子健康记录数据互通性的製造商。

策略竞争行动和以平台为中心的创新将决定诊断生态系统的准备度、弹性和长期差异化

POC 检测的竞争格局以策略伙伴关係、平台差异化以及对整合仪器、耗材和软体的整合解决方案的关注为特征。主要企业正在优先考虑支援多种检测格式的模组化平台架构，以实现更快的检测部署，并提升产品生命週期价值，以应对持续增长的耗材需求。同时，与连接供应商和医疗 IT 整合商合作，对于提供数据丰富的诊断结果，并将其融入临床工作流程和人口健康倡议，变得至关重要。

企业应采取切实可行的优先策略倡议，以确保诊断方法的采用、供应弹性和持续的商业性差异化

为了保持竞争力并保持临床相关性，行业领导者应采取一系列切实可行的倡议，使产品开发与业务现实和不断发展的护理模式保持一致。首先，透过优先考虑互通性和以使用者为中心的软体设计，实现与临床医生工作流程和电子健康记录的无缝集成，减少部署摩擦。其次，投资模组化平台策略，实现快速的检测可扩展性并支援多种样本类型，从而提高采购团队的灵活性，并减少对多台仪器的需求。

基于主要相关人员访谈、严格的二次研究和资料三角测量的透明且可复製的研究途径，以检验

本分析所采用的调查方法结合了定性和定量分析，旨在确保研究的严谨性、有效性和可重复性。主要研究包括对临床医生、实验室主任、采购负责人以及设备製造商和经销商的高级管理人员进行深入访谈，以了解实际使用案例、采购限制和未满足的需求。这些访谈也辅以机构层级的观察和对工作流程整合点的检验，将临床优先事项转化为产品需求。

结论性综合强调了平衡快速诊断途径、营运弹性和严格品管以实现临床影响的重要性

总而言之，即时检测正处于曲折点，技术日趋成熟，医疗服务模式的转变以及政策的转变正在共同重新定义诊断路径。虽然向分散式诊断的转变得益于检测化学、小型化设备和软体连接方面的进步，但这种转变也带来了营运、监管和供应链方面的挑战，需要刻意加以缓解。关税、不断变化的采购偏好以及区域监管的差异性增加了复杂性，相关人员必须透过灵活的采购、适应性强的产品架构和可靠的证据产生来应对这些挑战。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 分散的医疗机构和急诊对快速且准确的诊断的需求日益增加
  • 透过整合远端患者监护和虚拟医疗服务的即时检测来扩展远端医疗
  • 可携式多重免疫检测的普及使得在床边进行全面的多分析物检测成为可能
  • 利用快速即时药敏检测扩大分散式抗菌药物抗药性监测
  • 将一次性微流体盒与可重复使用的分析仪结合可降低测试成本
  • 越来越多地采用近患者凝血和止血监测进行门诊病人抗凝血治疗的管理和给药
  • 云端基础的品管和集中分析平台集成，以监控远端设备性能
  • 扩大急诊室的心臟生物标记照护现场检测可缩短治疗时间
  • 投资专为低资源和人道主义部署而设计的坚固耐用的诊断和太阳能 POC 设备
  • 使用可互通的无线连接标准，将 POC 结果即时安全地传输到 EHR

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章就地检验市场（按产品）

  • 消费服务和软体
    • 耗材及配件
    • 服务维护和校准
    • 软体和连接
  • 测量和分析设备
    • 桌上型分析仪
    • 分子平台
    • 可携式分析仪
    • 阅读器和扫描仪
  • 试剂和测定法
    • 血糖试纸
    • 血液学试剂
    • 免疫检测
    • 横向流动化验试剂
    • 分子检测试剂套件

第九章。就地检验市场（依测试类型）

  • 血气
  • 心臟标记物
    • B型利钠肽
    • 肌钙蛋白
  • 综合代谢组
  • 药物滥用检测
  • 血液学
    • 血液凝固检验
      • 活化部份凝血活酵素时间
      • 纤维蛋白原水平
      • 凝血酶原时间与国际标准化比
    • 全血球计数
  • 感染疾病
    • 胃肠道传染病检查
    • 呼吸道传染病检查
    • 性行为感染传染病检测
  • 分子诊断
  • 怀孕和不孕症治疗
  • 尿液检查

第 10 章。以样本类型就地检验市场

  • 血
  • 鼻腔和拭子样本
  • 唾液
  • 尿

第 11 章。就地检验市场（按技术）

  • 生物感测器电化学
  • 比色分析平台
  • 免疫检测
  • 横向流动化验
    • 抗体检测
    • 抗原检测
    • 多重侧流
  • 微流体
  • PCR和分子

第 12就地检验市场（依便携性）

  • 桌上型固定分析仪
  • 可携式手持设备

第 13 章。以采购方式就地检验市场

  • 市售测试套件
  • 处方笺测试

第十四章就地检验市场（依应用）

  • 慢性病管理
  • 急诊及严重治疗
  • 感染疾病诊断
  • 职业和职场测试
  • 肿瘤监测
  • 女性健康

第 15 章。就地检验）

  • 门诊治疗中心
  • 诊断实验室
  • 独立急诊科
  • 居家护理
  • 医院和诊所
  • 急诊医疗中心

第十六章就地检验市场（依通路）

  • 离线
    • 直销
    • 分销商和批发商
    • 零售和药局
  • 在线的

17. 美国就地检验市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

18. 欧洲、中东和非洲就地检验市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

19. 亚太地区就地检验市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第二十章 竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Abaxis, Inc. by Zoetis Inc
    • AccuBioTech Co., Ltd.
    • ACON Laboratories, Inc.
    • Beckman Coulter
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • CardioGenics Holdings Inc.
    • Chembio Diagnostic Systems, Inc. by Biosynex
    • Danaher Corporation
    • EKF Diagnostics Holdings
    • GE Healthcare Technologies, Inc.
    • Medtronic Plc
    • Nova Biomedical Corporation
    • OraSure Technologies, Inc.
    • Quidel Corporation
    • Radiometer Medical ApS
    • Randox Laboratories Ltd.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.

第21章 研究人工智慧

第22章 研究统计

第23章 研究联络人

第24章 研究报导

第25章 附录

Product Code: MRR-035AB9C0DA8B

The Point of Care Testing Market was valued at USD 32.87 billion in 2024 and is projected to grow to USD 37.13 billion in 2025, with a CAGR of 13.19%, reaching USD 69.17 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 32.87 billion
Estimated Year [2025] USD 37.13 billion
Forecast Year [2030] USD 69.17 billion
CAGR (%) 13.19%

A clear industry introduction highlighting how decentralized diagnostics, advanced assays, and digital convergence are redefining clinical decision pathways

Point of care testing continues to reshape diagnostics by bringing timely clinical decision-making closer to the patient. This introduction outlines the contemporary contours of the point of care testing ecosystem, emphasizing the convergence of decentralized diagnostics, digital connectivity, and therapeutic decision support. As health systems prioritize faster triage, value-based care, and outpatient management, point of care modalities are increasingly evaluated for their capacity to reduce clinical latency and improve patient experience.

Advances in miniaturized instrumentation, assay chemistry, and molecular methods now permit a broader range of analytes to be tested outside central laboratories. At the same time, software and connectivity tools are maturing to facilitate result integration with electronic health records and telehealth workflows. These developments are encouraging new use cases within emergency care, chronic disease monitoring, and community screening programs. Consequently, stakeholders across the value chain are recalibrating product development, reimbursement strategies, and distribution models to support rapid adoption while ensuring quality and regulatory compliance.

How converging advances in multiplexed assays, connectivity, and care delivery models are driving systemic change in decentralized diagnostic practice

The landscape of point of care testing is undergoing transformative shifts driven by technology, care delivery models, and patient expectations. First, the technological trajectory is moving from single-analyte rapid tests toward multiplexed platforms and integrated molecular workflows, enabling broader diagnostic breadth at the point of need. Concurrently, sensor miniaturization and microfluidic integration are reducing sample volume and turnaround time, which enhances feasibility for home and ambulatory environments.

Second, care delivery models are evolving: outpatient and community settings are absorbing responsibilities historically held by centralized laboratories, and telemedicine interfaces increasingly rely on near-real-time diagnostics to inform remote consultations. Third, the role of software and connectivity has intensified, with interoperability and cybersecurity becoming prerequisites for clinical adoption. Regulatory pathways are also adapting to accommodate decentralized diagnostics, creating opportunities as well as expectations for robust quality management systems. Finally, patient-centric trends-such as convenience, rapid reassurance, and longitudinal monitoring-are reshaping product design priorities, emphasizing user experience, simplified workflows, and clear result interpretation. Together, these shifts are not incremental but collectively redefine procurement decisions, clinical pathways, and competitive positioning across the ecosystem.

Assessing the multifaceted operational and supply chain consequences of United States tariff measures introduced in 2025 on point of care testing stakeholders

The imposition of tariffs and trade measures by the United States in 2025 introduces a complex set of effects for manufacturers, suppliers, and end users in the point of care testing space. Tariffs on components, consumables, and finished devices can elevate landed costs for products that rely on global supply chains, thereby influencing procurement strategies and reorder cadence. Since many instruments and reagents incorporate electronic components, plastics, and precision machined parts sourced from multiple geographies, tariff-driven cost escalation tends to be uneven and dependent on the origin of specific subcomponents.

In response to tariff pressures, manufacturers may accelerate regional sourcing strategies, increase vertical integration of critical elements, or relocate certain production activities to tariff-favored jurisdictions. These operational adjustments can mitigate exposure but often require near-term capital and redesign efforts. For healthcare providers and distributors, the cumulative effect of tariffs can shift purchasing towards products with more stable supply chain footprints, local assembly, or alternative suppliers offering comparable clinical performance. Pricing adjustments may also influence inventory policies, with stakeholders maintaining higher safety stocks to buffer against potential re-pricing or delays. Importantly, the regulatory and quality assurance implications of sourcing changes necessitate careful validation to ensure clinical equivalence, so organizations must balance cost-containment with the need to preserve test accuracy and continuity of care.

Comprehensive segmentation analysis uniting product, technology, test type, portability, purchase mode, application, end user, sample type, and distribution channel dynamics to inform strategy

Segmentation insights reveal how distinct product categories, test types, sample matrices, technologies, portability options, purchase modes, applications, end users, and distribution channels shape demand patterns and development priorities. Within product segmentation, consumables, services and software, instruments and analyzers, and reagents and assays each carry discrete implications: consumables, accessories and service maintenance and calibration, and software and connectivity underpin ongoing revenue streams and operational continuity; benchtop analyzers, molecular platforms, portable analyzers, and readers and scanners determine deployment scenarios and clinical workflows; while glucose test strips, hematology reagents, immunoassay reagents, lateral flow assay reagents, and molecular assay kits drive assay-specific supply chain and quality assurance requirements.

When viewed through test-type segmentation, the breadth from blood gases to infectious disease and molecular diagnostics affects instrument selection and clinician training, with cardiac markers and hematology requiring specialized assay robustness and coagulation testing demanding precise calibration and control across activated partial thromboplastin time, fibrinogen level, and prothrombin time and international normalized ratio assays. Infectious disease testing spans gastrointestinal, respiratory, and sexually transmitted infection panels, each influencing throughput needs and biosafety considerations. Sample-type segmentation, including blood, nasal and swab samples, saliva, and urine, informs collection device design, patient acceptability, and pre-analytical stability requirements. Technology segmentation differentiates biosensor electrochemical approaches, colorimetric platforms, immunoassays, lateral flow assays-spanning antibody, antigen, and multiplex formats-microfluidics, and PCR and molecular technologies, with each imparting trade-offs between sensitivity, specificity, cost, and operational complexity.

Portability options distinguish benchtop fixed analyzers from portable handheld devices, aligning device footprint with intended point of care settings. Mode of purchase segmentation separates over-the-counter accessibility from prescription-based dispensing, shaping labeling, user instructions, and post-market surveillance obligations. Application-driven segmentation-from chronic disease management to emergency and critical care, infectious disease diagnosis, occupational testing, oncology monitoring, and women's health-dictates performance thresholds and integration requirements with clinical care pathways. End-user segmentation that includes ambulatory care centers, diagnostic laboratories, free-standing emergency departments, home care, hospitals and clinics, and urgent care centers emphasizes differences in staffing, regulatory oversight, and capital acquisition processes. Finally, distribution channel segmentation across offline and online pathways, with offline methods such as direct sales, distributor and wholesale, and retail and pharmacy, impacts go-to-market strategies, margin structures, and customer support models. Taken together, these segmentation lenses provide a multifaceted view that guides product roadmaps, commercialization priorities, and lifecycle planning.

How geographic differences across the Americas, Europe Middle East and Africa, and Asia-Pacific shape procurement, regulation, and deployment of point of care diagnostics

Regional nuances significantly influence how point of care testing is designed, deployed, and reimbursed, with the Americas, Europe, Middle East and Africa, and Asia-Pacific each presenting distinct market drivers and operational considerations. In the Americas, health systems emphasize outpatient care optimization and chronic disease management, creating demand for devices and assays that support remote monitoring and rapid cardiovascular and metabolic testing in both clinic and home settings. Distribution networks in this region prioritize integrated supply chains and localized service support, which favors manufacturers that can demonstrate robust after-sales service and data interoperability with dominant electronic health records.

Europe, Middle East and Africa exhibit heterogeneity in regulatory regimes and healthcare infrastructure, with pockets of high regulatory rigor coexisting with areas where access barriers remain. This diversity requires adaptable product configurations and flexible pricing models. Interoperability standards and data privacy frameworks are especially influential in regulatory decision-making and clinical adoption in Europe, while capacity building and decentralized solutions are prioritized in many parts of the Middle East and Africa. In Asia-Pacific, rapid urbanization, expanding primary care networks, and high-volume public health screening initiatives drive demand for scalable, cost-effective point of care solutions. Regional manufacturing capabilities and supplier ecosystems in Asia-Pacific often accelerate product iteration cycles, and partnerships with local distributors are critical to achieve penetration across varied healthcare settings. Across all regions, reimbursement pathways, regulatory timelines, and customer training imperatives shape adoption velocity and product design choices.

Strategic competitive behaviors and platform-focused innovation that determine preparedness, resilience, and long-term differentiation within the diagnostic ecosystem

Competitive dynamics within the point of care testing landscape are characterized by strategic partnerships, platform differentiation, and a focus on integrated solutions that combine instruments, consumables, and software. Leading companies are prioritizing modular platform architectures that support multiple assay formats, enabling faster assay rollouts and improved lifetime value through recurring consumable demand. Concurrently, alliances with connectivity vendors and health IT integrators are becoming essential to deliver data-rich diagnostic results that plug into clinical workflows and population health initiatives.

Innovation strategies vary by firm, with some investing heavily in molecular and microfluidic technologies to expand the diagnostic menu, while others concentrate on low-cost lateral flow and biosensor technologies optimized for point-of-care ease of use. Service offerings, including field maintenance, calibration, and software updates, are being redefined as a competitive differentiator, and companies that can demonstrate rapid support turnaround and robust quality systems tend to secure larger institutional contracts. Supply chain resilience and localized manufacturing capabilities have also risen in strategic importance, prompting acquisitions and joint ventures to reduce exposure to global logistics disruptions. Finally, commercial models are shifting toward subscription and outcomes-based arrangements in select accounts, aligning vendor incentives with clinical performance and operational uptime.

Practical and prioritized strategic moves that companies should implement to secure adoption, supply resilience, and sustained commercial differentiation in diagnostics

To remain competitive and clinically relevant, industry leaders should pursue a set of actionable initiatives that align product development with operational realities and evolving care models. First, prioritize interoperability and user-centered software design so that devices integrate seamlessly into clinician workflows and electronic health records, thereby reducing friction at the point of adoption. Second, invest in modular platform strategies that allow rapid assay expansion and support multiple sample types, which increases flexibility for procurement teams and reduces the need for multiple device footprints.

Third, strengthen supply chain resilience through strategic regional sourcing, dual sourcing of critical components, and validated local assembly where feasible, which mitigates exposure to trade disruptions and tariff-driven cost pressures. Fourth, enhance post-market service offerings-particularly field maintenance and remote diagnostics-to preserve instrument uptime and protect clinical continuity. Fifth, adopt evidence-generation strategies that emphasize real-world performance, workflow impact, and patient-centric outcomes, thereby supporting payer discussions and clinical adoption. Finally, explore alternative commercial models, such as managed service agreements or outcome-linked contracts, to better align with healthcare purchasers' objectives and to create predictable revenue streams. Executing these actions with clear accountability and staged milestones will help firms convert technical capabilities into durable market advantage.

A transparent and reproducible research approach combining primary stakeholder interviews, rigorous secondary review, and data triangulation to validate conclusions

The research methodology underpinning this analysis integrates qualitative and quantitative approaches designed to ensure rigor, relevance, and reproducibility. Primary research consisted of in-depth interviews with clinicians, laboratory directors, procurement officers, and senior executives across device manufacturers and distributors to capture real-world use cases, procurement constraints, and unmet needs. These interviews were complemented by facility-level observations and validation of workflow integration points to translate clinical priorities into product requirements.

Secondary research included a systematic review of peer-reviewed clinical literature, regulatory guidance documents, industry standards for quality management and interoperability, and technical white papers describing assay and platform performance. Data triangulation techniques were employed to reconcile insights from diverse sources and to validate assumptions about operational behaviors and adoption barriers. The research also applied scenario analysis to assess supply chain risk and regulatory sensitivity, and key findings were stress-tested through expert panels to refine recommendations. Throughout, the methodology emphasized transparency, with audit trails linking conclusions to source materials and interview excerpts, ensuring that stakeholders can trace analytic judgments back to empirical evidence.

A conclusive synthesis emphasizing the balance between rapid diagnostic access, operational resilience, and rigorous quality controls to realize clinical impact

In conclusion, point of care testing is at an inflection point where technological maturity, changing care delivery models, and policy shifts are jointly redefining diagnostic pathways. The move toward decentralized diagnostics is supported by advances in assay chemistry, miniaturized instrumentation, and software connectivity, yet this transition also raises operational, regulatory, and supply chain challenges that require deliberate mitigation. Tariff actions, shifting procurement preferences, and regional regulatory heterogeneity add layers of complexity that stakeholders must address through resilient sourcing, adaptable product architectures, and robust evidence generation.

For manufacturers, the imperative is to deliver clinically rigorous, easy-to-use platforms that integrate seamlessly into workflows while offering sustainable service and supply models. For providers and payers, the focus should be on harnessing point of care capabilities to improve decision latency and patient experience without sacrificing quality controls. By aligning technology investments, commercial models, and implementation frameworks, stakeholders can realize the promise of point of care testing to deliver meaningful improvements in clinical care and operational efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Increasing demand for rapid, accurate diagnostics in decentralized healthcare settings and urgent care
  • 5.2. Expansion of telemedicine integrating POCT for remote patient monitoring and virtual healthcare services
  • 5.3. Proliferation of portable multiplex immunoassays enabling comprehensive multi-analyte panels at bedside
  • 5.4. Growth of decentralized antimicrobial resistance surveillance using rapid point of care susceptibility testing assays
  • 5.5. Emergence of disposable microfluidic cartridges paired with reusable analyzers to drive down per test costs
  • 5.6. Increased adoption of near-patient coagulation and hemostasis monitoring for outpatient anticoagulant management and dosing
  • 5.7. Integration of cloud-based quality control and centralized analytics platforms for remote device performance monitoring
  • 5.8. Scaling of point of care cardiac biomarker testing in emergency departments to reduce door to treatment times
  • 5.9. Investment in ruggedized diagnostics and solar powered POC devices tailored for low-resource and humanitarian deployments
  • 5.10. Adoption of interoperable wireless connectivity standards to enable secure real-time transmission of POC results to EHRs

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Point of Care Testing Market, by Product

  • 8.1. Introduction
  • 8.2. Consumables Services & Software
    • 8.2.1. Consumables & Accessories
    • 8.2.2. Service Maintenance & Calibration
    • 8.2.3. Software & Connectivity
  • 8.3. Instruments & Analyzers
    • 8.3.1. Benchtop Analyzers
    • 8.3.2. Molecular Platforms
    • 8.3.3. Portable Analyzers
    • 8.3.4. Readers & Scanners
  • 8.4. Reagents & Assays
    • 8.4.1. Glucose Test Strips
    • 8.4.2. Hematology Reagents
    • 8.4.3. Immunoassay Reagents
    • 8.4.4. Lateral Flow Assay Reagents
    • 8.4.5. Molecular Assay Kits

9. Point of Care Testing Market, by Test Type

  • 9.1. Introduction
  • 9.2. Blood Gases
  • 9.3. Cardiac Markers
    • 9.3.1. B-type Natriuretic Peptide
    • 9.3.2. Troponin
  • 9.4. Comprehensive Metabolic Panel
  • 9.5. Drug Of Abuse Testing
  • 9.6. Hematology
    • 9.6.1. Coagulation Tests
      • 9.6.1.1. Activated Partial Thromboplastin Time
      • 9.6.1.2. Fibrinogen Level
      • 9.6.1.3. Prothrombin Time & International Normalized Ratio
    • 9.6.2. Complete Blood Count
  • 9.7. Infectious Disease
    • 9.7.1. Gastrointestinal Infection Tests
    • 9.7.2. Respiratory Infection Tests
    • 9.7.3. Sexually Transmitted Infection Tests
  • 9.8. Molecular Diagnostics
  • 9.9. Pregnancy & Fertility
  • 9.10. Urinalysis

10. Point of Care Testing Market, by Sample Type

  • 10.1. Introduction
  • 10.2. Blood
  • 10.3. Nasal & Swab Samples
  • 10.4. Saliva
  • 10.5. Urine

11. Point of Care Testing Market, by Technology

  • 11.1. Introduction
  • 11.2. Biosensor Electrochemical
  • 11.3. Colorimetric Platforms
  • 11.4. Immunoassay
  • 11.5. Lateral Flow Assays
    • 11.5.1. Antibody Tests
    • 11.5.2. Antigen Tests
    • 11.5.3. Multiplex Lateral Flow
  • 11.6. Microfluidics
  • 11.7. PCR And Molecular

12. Point of Care Testing Market, by Portability

  • 12.1. Introduction
  • 12.2. Benchtop Fixed Analyzers
  • 12.3. Portable Handheld Devices

13. Point of Care Testing Market, by Mode of Purchase

  • 13.1. Introduction
  • 13.2. Over-The-Counter Tests
  • 13.3. Prescription-Based Tests

14. Point of Care Testing Market, by Application

  • 14.1. Introduction
  • 14.2. Chronic Disease Management
  • 14.3. Emergency And Critical Care
  • 14.4. Infectious Disease Diagnosis
  • 14.5. Occupational And Workplace Testing
  • 14.6. Oncology Monitoring
  • 14.7. Women Health

15. Point of Care Testing Market, by End User

  • 15.1. Introduction
  • 15.2. Ambulatory Care Centers
  • 15.3. Diagnostic Laboratories
  • 15.4. Free-Standing Emergency Departments
  • 15.5. Home Care
  • 15.6. Hospitals & Clinics
  • 15.7. Urgent Care Centers

16. Point of Care Testing Market, by Distribution Channel

  • 16.1. Introduction
  • 16.2. Offline
    • 16.2.1. Direct Sales
    • 16.2.2. Distributor & Wholesale
    • 16.2.3. Retail & Pharmacy
  • 16.3. Online

17. Americas Point of Care Testing Market

  • 17.1. Introduction
  • 17.2. United States
  • 17.3. Canada
  • 17.4. Mexico
  • 17.5. Brazil
  • 17.6. Argentina

18. Europe, Middle East & Africa Point of Care Testing Market

  • 18.1. Introduction
  • 18.2. United Kingdom
  • 18.3. Germany
  • 18.4. France
  • 18.5. Russia
  • 18.6. Italy
  • 18.7. Spain
  • 18.8. United Arab Emirates
  • 18.9. Saudi Arabia
  • 18.10. South Africa
  • 18.11. Denmark
  • 18.12. Netherlands
  • 18.13. Qatar
  • 18.14. Finland
  • 18.15. Sweden
  • 18.16. Nigeria
  • 18.17. Egypt
  • 18.18. Turkey
  • 18.19. Israel
  • 18.20. Norway
  • 18.21. Poland
  • 18.22. Switzerland

19. Asia-Pacific Point of Care Testing Market

  • 19.1. Introduction
  • 19.2. China
  • 19.3. India
  • 19.4. Japan
  • 19.5. Australia
  • 19.6. South Korea
  • 19.7. Indonesia
  • 19.8. Thailand
  • 19.9. Philippines
  • 19.10. Malaysia
  • 19.11. Singapore
  • 19.12. Vietnam
  • 19.13. Taiwan

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. F. Hoffmann-La Roche Ltd
    • 20.3.2. Abbott Laboratories
    • 20.3.3. Abaxis, Inc. by Zoetis Inc
    • 20.3.4. AccuBioTech Co., Ltd.
    • 20.3.5. ACON Laboratories, Inc.
    • 20.3.6. Beckman Coulter
    • 20.3.7. Becton, Dickinson and Company
    • 20.3.8. Bio-Rad Laboratories, Inc.
    • 20.3.9. bioMerieux SA
    • 20.3.10. CardioGenics Holdings Inc.
    • 20.3.11. Chembio Diagnostic Systems, Inc. by Biosynex
    • 20.3.12. Danaher Corporation
    • 20.3.13. EKF Diagnostics Holdings
    • 20.3.14. GE Healthcare Technologies, Inc.
    • 20.3.15. Medtronic Plc
    • 20.3.16. Nova Biomedical Corporation
    • 20.3.17. OraSure Technologies, Inc.
    • 20.3.18. Quidel Corporation
    • 20.3.19. Radiometer Medical ApS
    • 20.3.20. Randox Laboratories Ltd.
    • 20.3.21. Siemens Healthineers AG
    • 20.3.22. Thermo Fisher Scientific Inc.

21. ResearchAI

22. ResearchStatistics

23. ResearchContacts

24. ResearchArticles

25. Appendix

LIST OF FIGURES

  • FIGURE 1. POINT OF CARE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 20. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 22. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 26. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. ASIA-PACIFIC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 30. ASIA-PACIFIC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 31. POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 33. POINT OF CARE TESTING MARKET: RESEARCHAI
  • FIGURE 34. POINT OF CARE TESTING MARKET: RESEARCHSTATISTICS
  • FIGURE 35. POINT OF CARE TESTING MARKET: RESEARCHCONTACTS
  • FIGURE 36. POINT OF CARE TESTING MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 179. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 181. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 183. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
  • TABLE 185. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
  • TABLE 187. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 189. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
  • TABLE 193. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 195. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
  • TABLE 197. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 199. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 203. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 205. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
  • TABLE 207. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
  • TABLE 209. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 217. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 257. CANADA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 259. CANADA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 260. CANADA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
  • TABLE 261. CANADA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
  • TABLE 262. CANADA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
  • TABLE 263. CANADA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 265. CANADA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. CANADA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. CANADA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 268. CANADA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
  • TABLE 269. CANADA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 271. CANADA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. CANADA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
  • TABLE 273. CANADA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 274. CANADA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 275. CANADA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. CANADA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. CANADA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. CANADA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 279. CANADA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 280. CANADA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 281. CANADA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 282. CANADA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
  • TABLE 283. CANADA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
  • TABLE 284. CANADA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
  • TABLE 285. CANADA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. CANADA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 287. CANADA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. CANADA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 289. CANADA POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. CANADA POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 291. CANADA POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 292. CANADA POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 293. MEXICO POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 294. MEXICO POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 295. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 296. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
  • TABLE 297. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
  • TABLE 298. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
  • TABLE 299. MEXICO POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 300. MEXICO POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 301. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 304. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
  • TABLE 305. MEXICO POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 307. MEXICO POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
  • TABLE 309. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 310. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 311. MEXICO POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. MEXICO POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 313. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 315. MEXICO POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 316. ME